Topic: 5-HT2AR

Current therapies for Alcohol Use Disorder (AUD) exhibit significant variability in effectiveness, resulting in high relapse rates. Addressing this challenge requires a precision medicine approach incorporating biomarkers responsive to novel treatments. A promising approach involves bioelectronic devices utilising neuroelectric signatures of impaired prefrontal function, a key feature in AUD resulting in diminished inhibitory control over compulsive behaviour and increased vulnerability to relapse. Thus, we reason that event-related potentials and neural oscillations are valuable biomarkers fo

Treatment-resistant depression is a global public health concern, leaving a significant portion of the population without effective remedies. To address this issue, innovative strategies are urgently needed. Psilocybin, a non-selective 5-HT2AR agonist, has been found to alleviate depressive mood in individuals with treatment resistant depression (Carhart-Harris et al., 2017) Ketamine exhibits robust and enduring antidepressant properties both in patients and preclinical models. (Krystal et al., 2013). Sleep patterns are often affected by depressive disorders, making wireless EEG a valuable too

Treatment-resistant depression is a global public health concern, leaving a significant portion of the population without effective remedies. To address this issue, innovative strategies are urgently needed. Psilocybin, a non-selective 5-HT2AR agonist, has been found to alleviate depressive mood in individuals with treatment resistant depression (Carhart-Harris et al., 2017) Ketamine exhibits robust and enduring antidepressant properties both in patients and preclinical models. (Krystal et al., 2013). Sleep patterns are often affected by depressive disorders, making wireless EEG a valuable